Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when he expects NHS England and NICE to make a decision on licensing Kuvan for the treatment of phenylketonuria

NHS England has received a Preliminary Policy Proposal for the use of Sapropterin in the management of phenylketonuria for adults and children, as it is considered by the Clinical Lead that new evidence has now been published to support its use.

This was considered by the Specialised Services Clinical Panel where it was agreed that, as this is a licensed medicine, it should be referred to National Institute for Health and Care Excellence (NICE) for consideration through its technology appraisal process. NICE has confirmed receipt of referral and will be advising on the decision making process and timetable in due course.